TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25623603

Group type: EXPERIMENTAL
Intervention: Tailored intervention package including core and flexible components with embedded behaviour change techniques.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly detailed in the abstract).
Number of subjects: 0
Study: 23478476

Group type: EXPERIMENTAL
Intervention: Resistance training at 60% 1RM (month 2)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Resistance training at 70% 1RM (month 3)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Resistance training at 80% 1RM (month 4)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Postexercise hypotension analyses
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 64
Study: 21849603

Group type: EXPERIMENTAL
Intervention: Higher protein (HP; 2.9 and 4.4 g protein/100 kcal)
Number of subjects: 1138

Group type: COMPARATOR
Intervention: Lower protein (LP; 1.77 and 2.2 g protein/100 kcal)
Number of subjects: 1138

Group type: COMPARATOR
Intervention: Breastfed group
Number of subjects: 1138
Study: 20169858

Group type: EXPERIMENTAL
Intervention: Levocetirizine dihydrochloride orally disintegrating tablets with Indion‐204 as taste-masking agent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levocetirizine dihydrochloride orally disintegrating tablets with Tulsion‐335 as taste-masking agent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levocetirizine dihydrochloride orally disintegrating tablets with crospovidone as superdisintegrant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optimum formulation (F‐1) of levocetirizine dihydrochloride orally disintegrating tablets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Levocetirizine dihydrochloride orally disintegrating tablets
Number of subjects: 0
Study: 17944177

Group type: EXPERIMENTAL
Intervention: Tretinoin gel microsphere 0.04%
Number of subjects: 178

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 178
Study: 15554763

Group type: EXPERIMENTAL
Intervention: Tranylcypromine
Number of subjects: 77

Group type: COMPARATOR
Intervention: Phenelzine
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 77
Study: 14622808

Group type: EXPERIMENTAL
Intervention: Standardized exercise therapy with functional electrical muscle stimulation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standardized exercise therapy with placebo electrical stimulation
Number of subjects: 80
Study: 9040296

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 1436

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (tinzaparin sodium)
Number of subjects: 1436
Study: 7701032

Group type: EXPERIMENTAL
Intervention: Lactate infusion
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 9
Study: 3630934

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31599840

Group type: EXPERIMENTAL
Intervention: Bremelanotide 1.75 mg administered subcutaneously as needed
Number of subjects: 1267

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1267
Study: 28562168

Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC) monotherapy at an initial dose of 0.05-0.1 mg/kg/day
Number of subjects: 58

Group type: COMPARATOR
Intervention: Cyclophosphamide (CTX) combined with corticosteroids (prednisone 1 mg/kg/d) at a dose of 0.5-0.75 g/m2 once every month initially for 6 months
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Both TAC and CTX groups
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC) monotherapy
Number of subjects: 58
Study: 25952743

Group type: EXPERIMENTAL
Intervention: Percentage + risk label format
Number of subjects: 368

Group type: COMPARATOR
Intervention: Other 3 formats (frequency, percentage, frequency + risk label)
Number of subjects: 368
Study: 22994550

Group type: EXPERIMENTAL
Intervention: Placebo alcohol
Number of subjects: 77

Group type: COMPARATOR
Intervention: Soft drink
Number of subjects: 77
Study: 21543239

Group type: EXPERIMENTAL
Intervention: Low-dose zonisamide (3-4 mg/kg/day)
Number of subjects: 125

Group type: COMPARATOR
Intervention: High-dose zonisamide (6-8 mg/kg/day)
Number of subjects: 125
Study: 19327416

Group type: EXPERIMENTAL
Intervention: Periprocedural bleeding complications (none, mild, moderate, severe)
Number of subjects: 6995

Group type: EXPERIMENTAL
Intervention: Blood transfusion
Number of subjects: 6995
Study: 16969725

Group type: EXPERIMENTAL
Intervention: 20-pole Stablemapr mapping catheter (G1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional mapping (G2)
Number of subjects: 30
Study: 14976886

Group type: EXPERIMENTAL
Intervention: Shenfu injection (SFI) 1 ml/kg intravenous infusion 30 min before anesthesia
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 120
Study: 12588572

Group type: EXPERIMENTAL
Intervention: Home intervention including a diagnostic home visit, assessing the home for environmental hazards, advice about possible changes, offer of facilities for necessary home modifications, and training in the use of technical and mobility aids.
Number of subjects: 360

Group type: COMPARATOR
Intervention: Usual care at home (control group).
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Home intervention in a subgroup of participants with two or more falls in the year before recruitment.
Number of subjects: 360
Study: 10762749

Group type: EXPERIMENTAL
Intervention: Pion radiotherapy
Number of subjects: 215

Group type: COMPARATOR
Intervention: Photon radiotherapy
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Hormonal therapy
Number of subjects: 215
Study: 8985767

Group type: EXPERIMENTAL
Intervention: Plastic blunt cannula (PBC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two-way valve (2-way)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metal blunt cannula (MBC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional needled devices (Control)
Number of subjects: 0
Study: 1638661

Group type: EXPERIMENTAL
Intervention: Moving the place for vaccination close to the consulting room
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doctor writing a prescription recommending vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 2982538

Group type: EXPERIMENTAL
Intervention: Adrenaline infusion with intra-arterial propranolol
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Noradrenaline infusion with intra-arterial propranolol
Number of subjects: 6

Group type: COMPARATOR
Intervention: Doxazosin infusion
Number of subjects: 6

Group type: COMPARATOR
Intervention: Yohimbine infusion
Number of subjects: 6
Study: 30989763

Group type: EXPERIMENTAL
Intervention: Shelter services for women
Number of subjects: 183

Group type: COMPARATOR
Intervention: Shelter services for men
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Changes in social quality factors over time
Number of subjects: 183
Study: 29028364

Group type: EXPERIMENTAL
Intervention: Empowerment program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 27511182

Group type: EXPERIMENTAL
Intervention: Interferon beta‐1b (early treatment)
Number of subjects: 468

Group type: COMPARATOR
Intervention: Placebo (delayed treatment)
Number of subjects: 468

Group type: COMPARATOR
Intervention: MRI metrics
Number of subjects: 468
Study: 24361086

Group type: EXPERIMENTAL
Intervention: Subcutaneous diclofenac HPbCD administered in quadriceps
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Subcutaneous diclofenac HPbCD administered in gluteus
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Subcutaneous diclofenac HPbCD administered in abdomen
Number of subjects: 12
Study: 21584681

Group type: EXPERIMENTAL
Intervention: Carbohydrate supplementation (maltodextrin solution)
Number of subjects: 24
Study: 20369059

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted influenza vaccine (Sub/MF59)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Virosomal vaccine (SVV)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Split vaccine
Number of subjects: 199
Study: 18823656

Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg once a day, increased to 32 mg after 1 month
Number of subjects: 3326

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3326
Study: 16009798

Group type: EXPERIMENTAL
Intervention: Effective nasal continuous positive airway pressure (nCPAP) for 12 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sham nasal continuous positive airway pressure (nCPAP) for 12 weeks
Number of subjects: 27
Study: 12575879

Group type: EXPERIMENTAL
Intervention: HAMMER (hierarchical attribute matching mechanism for elastic registration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HAMMER
Number of subjects: 0
Study: 11864448

Group type: EXPERIMENTAL
Intervention: High-dose vitamins E (280 mg), C (100 mg), and beta-carotene (25 mg) daily for 20 weeks
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: High-dose vitamins E, C, and beta-carotene
Number of subjects: 100
Study: 7758899

Group type: EXPERIMENTAL
Intervention: 1500 aPTT units LMWH (Mono‐Embolex)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 5000 I.U. UFH
Number of subjects: 59

Group type: COMPARATOR
Intervention: No injection
Number of subjects: 59
Study: 2207852

Group type: EXPERIMENTAL
Intervention: Sanguinaria toothpaste and oral rinse regimen
Number of subjects: 260
Study: 7218971

Group type: EXPERIMENTAL
Intervention: Inversion
Number of subjects: 440

Group type: COMPARATOR
Intervention: Amputation
Number of subjects: 440
Study: 30849011

Group type: EXPERIMENTAL
Intervention: In-office tooth bleaching with 35% hydrogen peroxide for 45 minutes followed by at-home bleaching with 10% carbamide peroxide for 1 hour/day until satisfactory color is obtained.
Number of subjects: 26

Group type: COMPARATOR
Intervention: At-home bleaching with 10% carbamide peroxide for 1 hour/day until satisfactory color is obtained.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: In-office tooth bleaching with 35% hydrogen peroxide followed by at-home bleaching.
Number of subjects: 26
Study: 28735818

Group type: EXPERIMENTAL
Intervention: Curcuminoids (1000mg/day plus piperine 10mg/day)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo plus standard of care
Number of subjects: 118
Study: 25236187

Group type: EXPERIMENTAL
Intervention: Completion axillary lymph node dissection (ALND)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Intraoperative sentinel lymph node (SLN) analysis
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Extracapsular extension
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Reoperative surgery
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Intraoperative SLN analysis
Number of subjects: 180
Study: 23736369

Group type: EXPERIMENTAL
Intervention: Behavioral-risk information plus personal FHH-based risk assessment (BRI+FHH)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Behavioral-risk information (BRI)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Food safety control (Control)
Number of subjects: 221
Study: 21257114

Group type: EXPERIMENTAL
Intervention: Parent-based intervention (n = 133)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Standard care control condition (n = 131)
Number of subjects: 264
Study: 19321023

Group type: EXPERIMENTAL
Intervention: Private firm introduction consent form
Number of subjects: 0

Group type: COMPARATOR
Intervention: Shortened academic ethics committee consent form
Number of subjects: 0
Study: 16280255

Group type: EXPERIMENTAL
Intervention: Lopinavir GIQ (genotypic inhibitory quotient) calculated as the ratio between mean trough concentration and number of protease mutations
Number of subjects: 109
Study: 15330822

Group type: EXPERIMENTAL
Intervention: Local chilling and topical anti-inflammatory gel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraoral chilling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical application of a nonsteroidal anti-inflammatory drug
Number of subjects: 0
Study: 11483805

Group type: EXPERIMENTAL
Intervention: Radiant warmer
Number of subjects: 60

Group type: COMPARATOR
Intervention: Incubator
Number of subjects: 60
Study: 9769395

Group type: EXPERIMENTAL
Intervention: Arm A: IFO 2.2 g/m2 i.v. as a 4 h infusion on days 1-5, Mesna 600 mg i.v. as push injection at 0 h, 4 h, 8 h on days 1-5, CDDP 20 mg i.v. as a 60 min infusion on days 1-5, repeated every 28 days for 2 cycles.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Arm B: IFO 1.5 g/m2 i.v. as a 4 h infusion on days 1-5, Mesna 600 mg i.v. as push injection at 0 h, 4 h, 8 h on days 1-5, CDDP 20 mg i.v. as a 60 min infusion on days 1-5, repeated every 28 days for 3 cycles.
Number of subjects: 28
Study: 7918930

Group type: EXPERIMENTAL
Intervention: Flumecinol 600 mg once weekly for 3 weeks
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Flumecinol 300 mg daily for 3 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 3404165

Group type: EXPERIMENTAL
Intervention: IV glucose
Number of subjects: 8

Group type: COMPARATOR
Intervention: IV saline
Number of subjects: 8
Study: 8460757

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% with adrenaline (15 ml) administered by lumbar epidural injection 15 min before surgery (group A)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Bupivacaine 0.5% with adrenaline (15 ml) administered at the end of surgery (group B)
Number of subjects: 36
Study: 675848

Group type: EXPERIMENTAL
Intervention: RCK (Hoffman La Roche, Switzerland)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: SCK (BY Sorin‐IRE, Italy)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: ICK (Istituto Sieroterapico Milanese, Italy)
Number of subjects: 212
Study: 31855055

Group type: EXPERIMENTAL
Intervention: Natural polyphenolic extract from French maritime pine bark, Pycnogenol (PYC)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 28244292

Group type: EXPERIMENTAL
Intervention: Heated, humidified high-flow nasal cannula (HHFNC)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (nCPAP)
Number of subjects: 85
Study: 24928286

Group type: COMPARATOR
Intervention: Intravenous diazepam (DZP‐IV)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam (MDZ‐IM)
Number of subjects: 32
Study: 24145678

Group type: EXPERIMENTAL
Intervention: IV iron isomaltoside 1,000 (225 patients)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Oral iron sulfate (113 patients)
Number of subjects: 338
Study: 21781344

Group type: EXPERIMENTAL
Intervention: School-based intervention (2011-2012)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm (receive the intervention after the final follow-up assessment, 2013-2014)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 0
Study: 17935921

Group type: EXPERIMENTAL
Intervention: Transarterial infusion (TAI) with water-in-oil-in-water (W/O/W) emulsion containing epirubicin
Number of subjects: 18
Study: 17692105

Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 13129812

Group type: EXPERIMENTAL
Intervention: LY354740
Number of subjects: 0
Study: 10898131

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg b.i.d.
Number of subjects: 465

Group type: COMPARATOR
Intervention: Ofloxacin 200 mg b.i.d.
Number of subjects: 465
Study: 8996854

Group type: EXPERIMENTAL
Intervention: Voltaren (100 mg tablets)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Inflaban (100 mg enteric-coated tablets)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Voltaren
Number of subjects: 20

Group type: COMPARATOR
Intervention: Inflaban
Number of subjects: 20
Study: 1362250

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Angiography (MRA) for nonvascular pathology (n = 42)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Angiography (MRA) for vascular lesions (n = 108)
Number of subjects: 150
Study: 6364906

Group type: EXPERIMENTAL
Intervention: 0.25 mg terbutaline sulfate
Number of subjects: 7

Group type: COMPARATOR
Intervention: 0.25 ml normal saline solution (placebo)
Number of subjects: 7
Study: 31262366

Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cells (MSCs) embedded in a xenogenic scaffold
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 13
Study: 27943112

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 147

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 147
Study: 25528281

Group type: EXPERIMENTAL
Intervention: Weekly maintenance Cognitive Stimulation Therapy (CST) added to usual care for 24 weeks
Number of subjects: 236

Group type: COMPARATOR
Intervention: Usual care alone for 24 weeks
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: CST in combination with acetylcholinesterase inhibitors (ACHEIs)
Number of subjects: 236
Study: 23624802

Group type: EXPERIMENTAL
Intervention: pegylated interferon alpha‐2b (PEG‐IFNα‐2b) therapy
Number of subjects: 91

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: SOCS1 and SOCS3 mRNA levels
Number of subjects: 91
Study: 21285885

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (1200 mg/day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 19342599

Group type: EXPERIMENTAL
Intervention: Long-term fasting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic caloric restriction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endurance exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intralipid injection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-adrenergic agonist treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fatty acids
Number of subjects: 0
Study: 17356056

Group type: EXPERIMENTAL
Intervention: Inhaled mometasone 400 microg once daily for 8 weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 15036740

Group type: EXPERIMENTAL
Intervention: Femoral pulse assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brachial pulse assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Umbilical cord palpation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stethoscope assessment
Number of subjects: 0
Study: 11419379

Group type: EXPERIMENTAL
Intervention: Public condition (participants shared their answers and confidence ratings aloud)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Private condition (participants did not share their answers and ratings)
Number of subjects: 96
Study: 9189782

Group type: EXPERIMENTAL
Intervention: Sucrose ingested during exercise
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo ingested during exercise
Number of subjects: 6
Study: 8349988

Group type: EXPERIMENTAL
Intervention: Constant grip force of 11.3 kg (Group I)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Maximum grip effort resulting in a mean grip force of 30 kg (Group II)
Number of subjects: 66
Study: 3775265

Group type: EXPERIMENTAL
Intervention: Bacitracin
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 7

Group type: COMPARATOR
Intervention: Co-trimoxazol
Number of subjects: 7

Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 7

Group type: COMPARATOR
Intervention: Nalidixic acid
Number of subjects: 7

Group type: COMPARATOR
Intervention: Ofloxacin
Number of subjects: 7
Study: 30779431

Group type: EXPERIMENTAL
Intervention: Higher DDP countries
Number of subjects: 18627

Group type: COMPARATOR
Intervention: Higher restrictive alcohol policy
Number of subjects: 18627
Study: 28958052

Group type: EXPERIMENTAL
Intervention: AutoEPAP
Number of subjects: 25

Group type: COMPARATOR
Intervention: FixedEPAP
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: AutoEPAP and FixedEPAP
Number of subjects: 25
Study: 24638207

Group type: EXPERIMENTAL
Intervention: Probiotic lozenges containing Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp. lactis BB-12 (4 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lozenges without added probiotics (control group)
Number of subjects: 60
Study: 23817872

Group type: EXPERIMENTAL
Intervention: Omega-3 (3 g, Lovaza, GSK)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Omega-3
Number of subjects: 85
Study: 21574963

Group type: EXPERIMENTAL
Intervention: HES 130/0.42/6:1 (Venofundin(®))
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: HES 130/0.4/9:1 (Voluven(®))
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: HES 200/0.5/5:1 (Haes‐steril(®))
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 6% dextran 70 (Macrodex(®))
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: All colloids
Number of subjects: 84
Study: 19689920

Group type: EXPERIMENTAL
Intervention: Agomelatine
Number of subjects: 339

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 339

Group type: COMPARATOR
Intervention: Agomelatine and Placebo
Number of subjects: 339
Study: 16965560

Group type: EXPERIMENTAL
Intervention: Training for intervention clinicians (2 hours total, including a booster session and study materials)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Usual care by control clinicians
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Training for intervention clinicians
Number of subjects: 164
Study: 15286541

Group type: EXPERIMENTAL
Intervention: Standard therapy plus extracorporeal endotoxin adsorption
Number of subjects: 145

Group type: COMPARATOR
Intervention: Standard therapy alone for sepsis
Number of subjects: 145
Study: 11140431

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 500 microg administered twice daily via Diskhaler for 6 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 500 microg administered via Diskus or Diskhaler for 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) via either DPI
Number of subjects: 0
Study: 9338545

Group type: EXPERIMENTAL
Intervention: Nasal challenge with ragweed antigen extract
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intranasal beclomethasone before challenge
Number of subjects: 0
Study: 7701795

Group type: EXPERIMENTAL
Intervention: Prophylactic lymphadenectomy
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (no prophylactic lymphadenectomy)
Number of subjects: 67